Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00733746 | Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 123 | Alliance for Clinical Trials in OncologyOTHER | 2 | Oct 21, 2019 | clinicaltrials |
| NCT04130399 | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 1 | Oct 17, 2019 |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT02043730 | Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.(GAP) | completed | Phase 2 | 124 | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteOTHER | 1 | Oct 9, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02926183 | Study of NAC of GA Therapy for Patients With BRPC | unknown | Phase 2 | 60 | Wakayama Medical UniversityOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02362048 | ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer(KEYNOTE144) | completed | Phase 2 | 77 | Acerta Pharma BVINDUSTRY | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01524575 | Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 | withdrawn | Phase 2 | 0 | University of HawaiiOTHER | 1 | Sep 25, 2019 | clinicaltrials |
| NCT01505530 | A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer | completed | Phase 2 | 125 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 18, 2019 | clinicaltrials |
| NCT01028495 | A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer | completed | Phase 2 | 31 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 12, 2019 | clinicaltrials |
| NCT02338752 | Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02449967 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02718859 | Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02885727 | Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)(Panc-Durval+RT) | withdrawn | Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 0 | Sep 12, 2019 | clinicaltrials |
| NCT03008304 | High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT00813163 | Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer | completed | Phase 2 | 41 | PharmaEngineINDUSTRY | 2 | Sep 6, 2019 | clinicaltrials |
| NCT01648465 | Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors | terminated | Phase 2 | 25 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT02352831 | Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 16 | Washington University School of MedicineOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02570711 | Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer | terminated | Phase 2 | 3 | Acerta Pharma BVINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02999672 | A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 4 | Aug 28, 2019 | clinicaltrials |
| NCT02583477 | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 1 / Phase 2 | 23 | AstraZenecaINDUSTRY | 2 | Aug 14, 2019 | clinicaltrials |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B | withdrawn | Phase 1 / Phase 2 | 0 | Alan KatzOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT01858883 | Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 55 | Incyte CorporationINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02973672 | Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas | completed | Phase 1 / Phase 2 | 75 | SurgimabINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02124369 | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)(PRICKLE) | terminated | Phase 2 | 9 | CCTU- Cancer ThemeOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01313416 | Gemcitabine and CT-011 for Resected Pancreatic Cancer | terminated | Phase 2 | 2 | Augusta UniversityOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT03779464 | Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas | unknown | Phase 2 | 132 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT02736578 | Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery | terminated | Phase 2 | 8 | Eben RosenthalOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02737228 | Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 24 | CrystalGenomics, Inc.INDUSTRY | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01132755 | Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage | completed | Phase 2 | 112 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Hitendra PatelOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT03797443 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Piedmont Cancer InstituteOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT03432676 | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 30, 2019 | clinicaltrials |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Medical College of WisconsinOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT01893801 | Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA | completed | Phase 1 / Phase 2 | 25 | Pancreatic Cancer Research TeamOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT00219557 | AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 111 | PfizerINDUSTRY | 8 | May 14, 2019 | clinicaltrials |
| NCT03941457 | Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 9 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 8, 2019 | clinicaltrials |
| NCT03392571 | Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients | withdrawn | Phase 2 | 0 | Pancreatic Cancer Research TeamOTHER | 0 | May 7, 2019 | clinicaltrials |
| NCT03634332 | Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC | unknown | Phase 2 | 35 | Pancreatic Cancer Research TeamOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT01128296 | Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas | completed | Phase 1 / Phase 2 | 35 | Amer ZureikatOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT01088815 | Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | completed | Phase 2 | 98 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 26, 2019 | clinicaltrials |
| NCT03929094 | Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer | unknown | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Apr 26, 2019 | clinicaltrials |
| NCT00923299 | Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine(THERAPY) | completed | Phase 1 / Phase 2 | 33 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02910882 | PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer(HALO-IST) | terminated | Phase 2 | 4 | Scripps HealthOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies | terminated | Phase 2 | 5 | Washington University School of MedicineOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT00735917 | Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 3 | Apr 2, 2019 | clinicaltrials |
| NCT01978184 | Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine | completed | Phase 2 | 104 | Nathan Bahary, MDOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT00637247 | A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer | completed | Phase 2 | 142 | AmpliMed CorporationINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT00711997 | Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 9 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Mar 20, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Oct 21, 2019source: clinicaltrials